Amendments to the Claims:

This listing of claims will replace the version submitted on August 10, 2007.

1. (Currently amended) An activated compound having a formula:



(Formula 1)

wherein ~~the~~ an activated ~~compound~~ moiety is attached to the hydroxyl group and wherein the activated moiety ~~comprises an activating moiety~~ is selected from the group consisting of chloroformate, NHS carbonate, DSC para-nitrochloroformate, p-nitrochloroformate, phosgene and paranitrophenyl carbonate, and

where

R^1 is selected from the group consisting of alkyl, $-CH_2(OC_2H_4)OCH_3$, and $-(OC_2H_4)OCH_3$;

n is 0-4;

Olig is an oligomer having a formula:

where:

L is a optional linker moiety selected from the group consisting of $-CH_2O-$, $-CH_2OX-$, -OX-, -C(O)-, -C(O)X, -NH-, -NHC(O)-, -XNHC(O)-, -NHC(O)X, -C(O)NH-, -C(O)NHX-, and



where:

X is $alkyl_{1-6}$ or is not present,

Y is N or O or is not present, and

R^3 is $alkyl_{1-6}$;

PAG is a linear or branched polyalkylene glycol moiety;

R^2 is an $alkyl_{1-22}$ capping moiety if X is present or $alkyl_{2-22}$ if X is not present;

q is a number from 1 to 10 ~~the maximum number of branches on PAG~~; and

m is 1-5.

2. (Original) The compound of claim 1 comprising an Olig coupled to carbon 4 of the phenol moiety.

3. (Original) The compound of claim 1 comprising an Olig coupled to carbon 3 of the phenol moiety, and/or an Olig coupled to carbon 5 of the phenol moiety.

4. (Original) The compound of claim 1 wherein m is 1 and the Olig is coupled to carbon 4 of the phenol moiety.

5. (Original) The compound of claim 1 wherein m is 1 and the Olig is coupled to carbon 3 or carbon 5 of the phenol moiety.

6. (Original) The compound of claim 1 wherein:
   (a) m is 2, and
   (b) a first Olig is coupled to carbon 3 of the phenol moiety, and
   (c) a second Olig is coupled to carbon 5 of the phenol moiety.

7. (Original) The compound of claim 1 wherein L is present and X is not present.

8. (Original) The compound of claim 1 wherein L and X are both present.

9. (Original) The compound of claim 1 wherein PAG is a linear polyalkylene glycol moiety.

10. (Original) The compound of claim 1 wherein PAG is a linear polyethylene glycol moiety.

11. (Original) The compound of claim 1 wherein PAG is a branched polyalkylene glycol moiety.

12. (Original) The compound of claim 1 wherein PAG is a branched polyethylene glycol moiety.

13. (Original) The compound of claim 1 wherein q is 1 to 5.

14. (Original) The compound of claim 1 wherein q is 2.

15. (Original) The compound of claim 1 wherein R^2 is alkyl $_{5-12}$.

16. (Original) The compound of claim 1 wherein R^2 is alkyl $_{1-4}$.

17. (Original) The compound of claim 1 wherein X is present and R^2 is methyl.

18. (Original) The compound of claim 1 wherein R^1 is alkyl$_{1-22}$.

19. (Original) The compound of claim 1 wherein R^1 is alkyl$_{1-12}$.

20. (Original) The compound of claim 1 wherein R^1 is alkyl$_{1-6}$.

21. (Original) The compound of claim 1 wherein R^1 is methyl and L is not amide or O.

22. (Original) The compound of claim 1 wherein R^1 is methyl.

23. (Cancelled)

24. (Cancelled)

25. (Currently amended) The activated compound of claim 1 further comprising a protein drug moiety, wherein the protein drug moiety is insulin. ~~A biologically active agent comprising a compound of claim 1 covalently coupled thereto by a carbamate bond to form a prodrug which does or does not retain the biological activity of the biologically active agent, wherein the biologically active agent is a drug moiety or a protein drug moiety~~.

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled) :

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35. (Cancelled)

24
~~36~~. (Currently amended) A compound having a formula:



wherein

X is an alkyl or is not present;

PEG is linear or branched PEG_{2-50};

R is H or alkyl;

n is from 1 to 10 ~~the maximum number of PEG branches~~; and

R^1 is alkyl.

37. (Cancelled)

38. (Cancelled)

39. (Cancelled)

40. (Cancelled)

41. (Cancelled)

42. (Cancelled)

25 ~~43~~. (Previously presented) A compound having a formula:



(Compound 7).

26 ~~44~~. (Original) The compound of claim 1, wherein the compound is a pure prodrug or partial prodrug.

27 ~~45~~. (Original) A pharmaceutical composition comprising the compound of claim 1 in a pharmaceutically acceptable carrier.

46. (Cancelled)

28 47. (Previously presented) A method of treating a subject in need of treatment for diabetes comprising administering an effective amount of the activated compound of claim 1 that is conjugated to insulin to the subject.